Uma Dutta

Dr. Uma Dutta

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in Biomimetics
Verified
Journal Article
Open access
PDF file
OAOsama Al-Baik
Osama Al-Baik
SASALEH ALOMARI
SALEH ALOMARI
OAOmar Alsayyed
Omar Alsayyed
Saikat GochhaitSaikat Gochhait
Saikat Gochhait
ILIrina Leonova
Irina Leonova
Mohammad DehghaniMohammad Dehghani
Mohammad Dehghani
A new bio-inspired metaheuristic algorithm named the Pufferfish Optimization Algorithm (POA), that imitates the natural behavior of pufferfish in nature, is introduced in this paper. The fundamental inspiration of POA is adapted from the defense mechanism of pufferfish against predators. In this defense mechanism, by filling its elastic stomach with water, the pufferfish becomes a spherical ball with pointed spines, and as a result, the hungry predator escapes from this threat. The POA theory is stated and then mathematically modeled in two phases: (i) exploration based on the simulation of a predator’s attack on a pufferfish and (ii) exploitation based on the simulation of a predator’s escape from spiny spherical pufferfish. The performance of POA is evaluated in handling the CEC 2017 test suite for problem dimensions equal to 10, 30, 50, and 100. The optimization results show that POA has achieved an effective solution with the appropriate ability in exploration, exploitation, and the balance between them during the search process. The quality of POA in the optimization process is compared with the performance of twelve well-known metaheuristic algorithms. The simulation results show that POA provides superior performance by achieving better results in most of the benchmark functions in order to solve the CEC 2017 test suite compared to competitor algorithms. Also, the effectiveness of POA to handle optimization tasks in real-world applications is evaluated on twenty-two constrained optimization problems from the CEC 2011 test suite and four engineering design problems. Simulation results show that POA provides effective performance in handling real-world applications by achieving better solutions compared to competitor algorithms.

1 February 2021 in Life Sciences
Verified
Journal Article
Closed access
SASemim Akhtar Ahmed
Semim Akhtar Ahmed
DPDey Parama
Dey Parama
EDEnush Daimari
Enush Daimari
SGSosmitha Girisa
Sosmitha Girisa
KBKishore Banik
Kishore Banik
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara

10 July 2021 in Molecular Biomedicine
Verified
Journal Article
Open access
PDF file
SGSosmitha Girisa
Sosmitha Girisa
SHSahu Henamayee
Sahu Henamayee
DPDey Parama
Dey Parama
VRVarsha Rana
Varsha Rana
UDUma Dutta
Uma Dutta
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Cancer is one of the lethal diseases that arise due to the molecular alterations in the cell. One of those alterations associated with cancer corresponds to differential expression of Farnesoid X receptor (FXR), a nuclear receptor regulating bile, cholesterol homeostasis, lipid, and glucose metabolism. FXR is known to regulate several diseases, including cancer and cardiovascular diseases, the two highly reported causes of mortality globally. Recent studies have shown the association of FXR overexpression with cancer development and progression in different types of cancers of breast, lung, pancreas, and oesophagus. It has also been associated with tissue-specific and cell-specific roles in various cancers. It has been shown to modulate several cell-signalling pathways such as EGFR/ERK, NF-κB, p38/MAPK, PI3K/AKT, Wnt/β-catenin, and JAK/STAT along with their targets such as caspases, MMPs, cyclins; tumour suppressor proteins like p53, C/EBPβ, and p-Rb; various cytokines; EMT markers; and many more. Therefore, FXR has high potential as novel biomarkers for the diagnosis, prognosis, and therapy of cancer. Thus, the present review focuses on the diverse role of FXR in different cancers and its agonists and antagonists.

26 September 2022 in Cancer Investigation
Verified
Journal Article
Closed access
RVRamya Venkat
Ramya Venkat
EVElika Verma
Elika Verma
UDUzini Devi Daimary
Uzini Devi Daimary
AKAviral Kumar
Aviral Kumar
SGSosmitha Girisa
Sosmitha Girisa
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
With rising technological advancements, several factors influence the lifestyle of people and stimulate chronic inflammation that severely affects the human body. Chronic inflammation leads to a broad range of physical and pathophysiological distress. For many years, non-steroidal drugs and corticosteroids were most frequently used in treating inflammation and related ailments. However, long-term usage of these drugs aggravates the conditions of chronic diseases and is presented with morbid side effects, especially in old age. Hence, the quest for safe and less toxic anti-inflammatory compounds of high therapeutic potential with least adverse side effects has shifted researchers’ attention to ancient medicinal system. Resveratrol (RSV) − 3,4,5′ trihydroxystilbene is one such naturally available polyphenolic stilbene derivative obtained from various plant sources. For over 2000 years, these plants have been used in Asian medicinal system for curing inflammation-associated disorders. There is a wealth of in vitro, in vivo and clinical evidence that shows RSV could induce anti-aging health benefits including, anti-cancer, anti-inflammatory, anti-oxidant, phytoesterogenic, and cardio protective properties. However, the issue of rapid elimination of RSV through the metabolic system and its low bio-availability is of paramount importance which is being studied extensively. Therefore, in this article, we scientifically reviewed the molecular targets, biological activities, beneficial and contradicting effects of RSV as evinced by clinical studies for the prevention and treatment of inflammation-mediated chronic disorders.

2 December 2022
Verified
Book Chapter
Closed access
PDF file
UDUma Dutta
Uma Dutta
NBNikhil Danny Babu
Nikhil Danny Babu
GSGirish S. Setlur
Girish S. Setlur

1 June 2025 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
UDUma Dutta
Uma Dutta
SDSonali Dey
Sonali Dey
MBMonikongkona Boruah
Monikongkona Boruah
BSBethsebie Lalduhsaki Sailo
Bethsebie Lalduhsaki Sailo
BMBhaigyaroti Muchahary
Bhaigyaroti Muchahary
AKAjaikumar B Kunnumakkara
Ajaikumar B Kunnumakkara
Objective: Oral squamous cell carcinoma (OSCC), affecting the lip and oral cavity, is one of the most prevalent cancers worldwide with the highest morbidity rate in the North-Eastern region of India. The current treatment options including surgery and chemotherapy are plagued by adverse side-effects and emergence of chemo-resistance, particularly against drugs like cisplatin and 5-fluorouracil. The present study focuses on demonstrating the effects of diosgenin, a naturally occurring steroidal saponin, on the survival, proliferation, and migration of OSCC cells in vitro. Methods: Preliminary in vitro screening of diosgenin in OSCC cells was performed using MTT, colony formation, cell cycle arrest, PI-FACS, live/dead, and wound-healing assays. In addition, the potential of diosgenin in regulating the expression of critical proteins involved in OSCC was evaluated using western blot analysis. Result: The present study shows that diosgenin exhibited selective anti-proliferative activity on OSCC cell lines SAS and HSC3 compared to normal kidney cell line HEK-293T. In addition, it enhances the chemosensitivity of SAS cells to cisplatin and 5-FU. This compound also displayed anti-clonogenic, cell cycle arrest, cytotoxic, and anti-migratory effects on SAS cells in a dose-dependent manner. Further, diosgenin regulated the expressions of COX-2, CXCR-4, VEGF, TWIST-1, p-AKT, and AKT, which are critical proteins for the development and progression of OSCC. Conclusion: These findings support the therapeutic potential of diosgenin, thereby opening a new avenue for oral cancer therapy. Nonetheless, the data needs to be further validated in in vivo and clinical settings.